Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Ascentage Pharma Group International (AAPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: AAPG (3-star) is a STRONG-BUY. BUY since 77 days. Profits (61.41%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
0 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
Analysis of Past Performance
Type Stock | Historic Profit 61.41% | Avg. Invested days 77 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.35B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1 | 52 Weeks Range 16.50 - 40.81 | Updated Date 05/15/2025 |
52 Weeks Range 16.50 - 40.81 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Earnings Date
Report Date 2025-07-03 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -39.9% | Operating Margin (TTM) 22.82% |
Management Effectiveness
Return on Assets (TTM) -7.14% | Return on Equity (TTM) -52.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1665238458 | Price to Sales(TTM) 7.03 |
Enterprise Value 1665238458 | Price to Sales(TTM) 7.03 | ||
Enterprise Value to Revenue 13.44 | Enterprise Value to EBITDA - | Shares Outstanding 348267008 | Shares Floating 174845965 |
Shares Outstanding 348267008 | Shares Floating 174845965 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Ascentage Pharma Group International
Company Overview
History and Background
Ascentage Pharma Group International, founded in 2009, is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for cancer, age-related diseases, and other life-threatening conditions. It has evolved from a research-focused entity to a commercial-stage company.
Core Business Areas
- Drug Discovery and Development: Research and development of small molecule drugs targeting key proteins and pathways involved in cancer and other diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
- Commercialization: Marketing and sales of approved drugs.
Leadership and Structure
The company is led by a team of experienced pharmaceutical executives and scientists. Its organizational structure includes departments for research, development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Olverembatinib (HQP1351): A third-generation BCR-ABL inhibitor for patients with T315I-mutated chronic myeloid leukemia (CML). Market share is still emerging. Competitors include Novartis (Gleevec, Tasigna, Scemblix), Bristol Myers Squibb (Sprycel), and Takeda (Iclusig).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with companies investing heavily in research and development. The market for cancer therapies is growing rapidly due to an aging population and increasing incidence of cancer.
Positioning
Ascentage Pharma Group International is positioned as an innovative biopharmaceutical company focused on developing novel therapies for unmet medical needs. Its competitive advantage lies in its expertise in developing small molecule inhibitors and its focus on specific cancer targets.
Total Addressable Market (TAM)
The global oncology market is expected to reach billions of dollars. Ascentage is positioned to address unmet needs within specific cancer subtypes, capturing a segment of this vast market.
Upturn SWOT Analysis
Strengths
- Innovative drug development platform
- Experienced management team
- Strong pipeline of drug candidates
- Global partnerships
Weaknesses
- Limited commercial infrastructure
- Reliance on external funding
- High R&D costs
- Concentration on a few therapeutic areas
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships with larger pharmaceutical companies
- Increasing demand for cancer therapies
- Regulatory approval of new drugs
Threats
- Competition from larger pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- NVS
- BMY
- TAK
Competitive Landscape
Ascentage Pharma Group International faces intense competition from larger pharmaceutical companies with greater resources. However, its innovative drug development platform and focus on specific cancer targets provide a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancements in its clinical pipeline and strategic partnerships.
Future Projections: Future growth is expected to be driven by regulatory approvals of its drug candidates and commercial expansion.
Recent Initiatives: Recent initiatives include expanding its clinical trials, forging new partnerships, and preparing for commercial launches.
Summary
Ascentage Pharma Group International is an innovative biopharmaceutical company with a promising pipeline of cancer therapies. It is still an emerging company, but its strengths lie in drug development and its management team. It needs to focus on commercializing the product and overcoming the limited commercial infrastructure and Reliance on external funding. Competition from major players is one major concern.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be limited due to the company's listing status.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ascentage Pharma Group International
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-01-24 | Co-Founder, Chairman & CEO Dr. Dajun Yang M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 567 | Website https://www.ascentage.cn |
Full time employees 567 | Website https://www.ascentage.cn | ||
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is also involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.